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The incidence of multiple myeloma (MM) is known to be variable according to ethnicity. However, the differences
in clinical characteristics between ethnic groups are not well-defined. In Asian countries, although the incidence
of MM has been lower than that of Western countries, there is growing evidence that MM is increasing rapidly.
The Asian Myeloma Network decided to initiate the first multinational project to describe the clinical
characteristics of MM and the clinical practices in Asia. Data were retrospectively collected from 23 centers in 7
countries and regions. The clinical characteristics at diagnosis, survival rates and initial treatment of 3,405
symptomatic MM patients were described. Median age was 62 years (range, 19–106), with 55.6% of being male.
Median overall survival (OS) was 47 months (95% CI 44.0–50.0). Stem cell transplantation was performed in 666
patients who showed better survival rates (79 vs. 41 months, P<0.001). The first-line treatments of 2,970 patients
were analyzed. The overall response rate was 71% including very good partial response or better in 31% of the
2,660 patients those were able to be evaluated. New drugs including bortezomib, thalidomide, and lenalidomide
were used in 36% of 2,970 patients and affected OS when used as a first-line treatment.
Am. J. Hematol. 89:751–756, 2014. VC 2014 Wiley Periodicals, Inc.
 Introduction
Multiple myeloma (MM) is one of the most common hematologic malignancies, with 103,826 new cases and 72,453 deaths annually, compris-
ing 0.8% and 1% of all cancers, respectively [1]. Its incidence is known to vary by ethnicity, with Asians showing a relatively lower incidence than
Caucasians [1]. However, recent reports have suggested that the incidence of MM is increasing in some Asian countries [2,3]. There have been
reports describing the clinical profiles [4–6] as well as the cytogenetic characteristics [7–9] of MM in Asia, with some studies revealing unique
findings in their national cohorts. There have also been reports describing unique drug toxicity profiles such as interstitial pneumonitis among Jap-
anese bortezomib users [10,11], as well as lower incidence of thromboembolism among thalidomide users in some Asian countries, even without
antithrombotic prophylaxis, strongly suggesting differences in pharmacogenomics [12,13]. Although several studies on the clinical features of MM
in Asian countries have been published, all of them were nationwide studies that did not include a variety of Asian ethnicities and did not incor-
porate recent changes in epidemiology and medical practices. Recognizing the need for Asian multi-national studies, the Asian Myeloma Network
(AMN) was launched in March 2011 under the auspices of the International Myeloma Foundation (IMF) with the participation of 7 countries and
regions which already had national myeloma study groups at the time: China, Hong Kong, Japan, Korea, Singapore, Taiwan, and Thailand. For
our first project, we conducted a multinational study to define the clinical characteristics of MM in Asian countries. Our key question was whether
MM in Asia has characteristics that differ from its presentation in Western countries.
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 Methods
Patients. Data from 3,405 symptomatic myeloma patients was collected from
tertiary centers of seven countries/regions: China, Hong Kong, Japan, Korea, Singa-
pore, Taiwan, and Thailand. The number of patients was not distributed according
to the population or size of respective countries or regions as the study was
designed to include about 500 cases from each country or region. The year of diag-
nosis ranged from 1986 to 2011. Clinical and laboratory data at the time of diagno-
sis and data on treatment were retrospectively collected from medical records and
existing databases. The data were sent to the principal investigators as written case
record forms or electronic data forms. Each patient’s data was labeled with a
unique identification number to minimize the risk of exposing private medical
information. The study protocol was approved by institutional review boards in
accordance with the declaration of Helsinki.
Statistical analysis. The Chi-square test was used to test the correlation of cate-
gorical variables, with the Fisher’s exact test applied when appropriate. The distri-
bution of continuous variables across different groups was compared using the
Student’s t test or the Mann-Whitney U test. Overall survival (OS) was estimated
from the date of the diagnosis until the date of death or the last follow-up for living
patients. Patients who were lost to follow-up were censored at the date of last con-
tact. Cumulative survival curves were plotted according to the Kaplan and Meier
method. The log-rank test was used to compare survival differences among categor-
ical variables. The Cox proportional hazard model was used for multivariate analy-
sis of OS. Due to missing data, three different multivariate analyses were conducted
with different sets of variables: baseline characteristics in combination with treat-
ment variables, cytogenetics or FISH results. All p values were 2-sided, with 0.05
chosen as the level of statistical significance. All statistical analyses were performed
using a statistical software package (SPSS, Version 20.0, and Chicago, IL).
 Results
Clinical characteristics
The median age of all patients was 62 years (range, 19–106), and
55.6% were male. The most common heavy chain type was IgG
(55.2%), followed by IgA (22.0%). Light chain disease (17.9%) was
the third common myeloma subtype. Bone lesions were documented
in 60.2% of the patients and extramedullary plasmacytoma in 15.4%
of the patients. Hypercalcemia, significant azotemia, significant ane-
mia, and thrombocytopenia were presented in 16.7%, 23.4%, 60.7%,
and 8.8% of patients, respectively. The International Stage System
TABLE I. Clinical Characteristics of the Patients
Total China Hong Kong Japan Korea Singapore Taiwan Thailand
No of centers 23 3 1 3 3 2 1 10
N 3405 798 109 601 587 493 414 403
% 100 23.4 3.2 17.7 17.2 14.5 12.2 11.8
Age median 62 59 65 66 61 62 63 59
range 19–106 23–106 35–93 29–90 23–93 25–93 24–90 19–95
< 65 58.5% 68.4% 48.6% 42.1% 63.7% 55.6% 53.1% 67.5%
 65 41.5% 31.6% 51.4% 57.9% 36.3% 44.4% 46.9% 32.5%
Gender Female 44.4% 38.6% 32.1% 49.4% 46.7% 48.7% 35.0% 53.1%
Male 55.6% 61.4% 67.9% 50.6% 53.3% 51.3% 65.0% 46.9%
Heavy Chain Type N 3129 736 99 594 587 481 406 226
IgG 55.2% 50.4% 48.5% 58.8% 48.6% 63.4% 50.2% 65.5%
IgA 22.0% 23.2% 18.2% 19.7% 24.2% 20.8% 23.9% 19.5%
IgD 3.1% 6.0% 7.1% 3.4% 1.5% 1.0% 3.2% 0.0%
LCD 17.9% 17.8% 23.2% 17.3% 20.6% 13.3% 20.9% 15.0%
Non–secretory 1.9% 2.3% 0.0% 0.7% 4.3% 1.2% 1.5% 0.0%
Hemoglobin N 3271 759 104 572 587 470 377 402
10.0 g/dl 39.3% 37.4% 44.2% 46.2% 41.9% 40.2% 37.4% 29.1%
<10.0 g/dl 60.7% 62.6% 55.8% 53.8% 58.1% 59.8% 62.6% 70.9%
Platelets N 3157 734 15 574 587 468 376 403
<70 X 109/l 8.8% 10.1% 6.7% 12.9% 5.6% 5.3% 10.1% 7.9%
70 X 109/l 91.2% 89.9% 93.3% 87.1% 94.4% 94.7% 89.9% 92.1%
Bone lesion N 2661 201 88 570 581 404 414 403
yes 60.2% 74.6% 73.9% 80.0% 67.3% 46.3% 57.2% 28.5%
no 39.8% 25.4% 26.1% 20.0% 32.7% 53.7% 42.8% 71.5%
Extramedullary plasmacytoma N 3093 797 99 580 585 353 414 265
presence 15.4% 15.6% 20.2% 5.2% 23.9% 14.2% 12.6% 22.6%
absence 84.6% 84.4% 79.8% 94.8% 76.1% 85.8% 87.4% 77.4%
Serum creatinine N 3173 709 71 571 587 462 373 400
<2.0 mg/dl 76.6% 76.0% 80.3% 83.9% 82.8% 75.1% 69.2% 66.5%
2.0 mg/dl 23.4% 24.0% 19.7% 16.1% 17.2% 24.9% 30.8% 33.5%
Serum albumin N 3030 686 93 588 587 454 235 387
<3.5 g/dl 52.0% 51.6% 52.7% 40.6% 52.0% 63.9% 39.6% 63.3%
3.5 g/dl 48.0% 48.4% 47.3% 59.4% 48.0% 36.1% 60.4% 36.7%
Serum beta 2-microglobulin N 2857 660 62 507 587 403 324 314
<3.5 mg/l 34.5% 29.1% 37.1% 41.6% 35.6% 39.7% 37.3% 22.6%
3.5–5.5 mg/l 23.4% 22.0% 35.5% 26.0% 25.9% 24.3% 18.8% 18.5%
>5.5 mg/l 42.1% 48.9% 27.4% 32.3% 38.5% 36.0% 43.8% 58.9%
ISS N 2984 775 59 532 587 446 273 312
I 19.9% 16.5% 25.4% 30.8% 22.1% 15.5% 18.3% 12.2%
II 36.1% 32.8% 45.8% 36.8% 39.4% 44.4% 29.7% 28.5%
III 44.0% 50.7% 28.8% 32.3% 38.5% 40.1% 52.0% 59.3%
Serum calcium N 3063 670 69 570 587 408 367 392
10.5 mg/dl 16.7% 13.1% 40.6% 13.5% 11.9% 13.5% 19.6% 31.1%
<10.5 mg/dl 83.3% 86.9% 59.4% 86.5% 88.1% 86.5% 80.4% 68.9%
Plasma cells of BM N 3042 723 64 529 587 385 382 372
<30% 41.1% 51.6% 42.2% 55.6% 35.9% 36.4% 30.9% 23.1%
30–70% 40.5% 36.8% 35.9% 35.9% 45.3% 48.1% 41.9% 38.2%
>70% 18.4% 11.6% 21.9% 8.5% 18.7% 15.6% 27.2% 38.7%
LCD, light chain disease; ISS, international staging system; BM, bone marrow.
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(ISS) was 19.9%/36.1%/44.0% for stages I/II/III, respectively. Detailed
baseline characteristics are summarized in Table I. The median over-
all survival (OS) was 47 months (95% CI 44.0–50.0) (Fig. 1A).
Cytogenetics
Conventional cytogenetic results were available in 1,681 patients and
FISH results were available in a smaller subset of patients due to the
variable capabilities of the study centers over various time periods. We
could gather the results of FISH for t(11;14)/ t(4;14)/ t(14;16)/ 17p dele-
tions from 683/637/498/854 patients, respectively. The proportion of
each genetic abnormality observed and overall survival are summarized
in Table II. Abnormal cytogenetics was observed in 32.5% of the
patients. The rates of diploidy/hyperdiploidy/nonhyperdiploidy were
70.1%/14.8%/15.1%, respectively. 13q deletions were detected in 12.2%
of the patients by conventional cytogenetics. By FISH study, the rates of
t(11;14)/t(4;14)/t(14;16)/17p deletions were 17.4%/10.5%/4.4%/13.3%,
respectively. The Chinese data showed a higher incidence of 17p dele-
tions. On univariate analyses the presence of abnormal conventional
cytogenetics, non-ploidy karyotype, 13q deletion, and t(4;14) were asso-
ciated with significant negative impact on overall survival (P< 0.05),
while the 17p deletion by FISH was associated with a nonsignificant
trend towards an inferior survival outcome (P5 0.061).
Treatment
Treatment characteristics and response outcomes are summarized
in Table III. Autologous transplantation was conducted in 19.8% (666
patients).The first-line treatment of 2,970 patients was analyzed. The
overall response rate was 71%, with a very good partial response
(VGPR) or better observed in 31% of the 2660 evaluable patients.
New drugs including bortezomib, thalidomide, and lenalidomide were
administered to 36% of 2,970 patients and they impacted on the over-
all survival on multivariate analysis.
Survival and prognostic factors
The clinical parameters affecting overall survival by univariate analy-
sis were age, hemoglobin, platelets, extramedullary plasmacytoma, bone
marrow plasma cells, serum calcium, serum albumin, serum creatinine,
serum beta-2 microglobulin, heavy chain type, and ISS (Table IV). OS
of patients who were diagnosed in recent 10 years was better than those
who were diagnosed before (Fig. 1B). Autologous stem cell transplanta-
tion (ASCT) and response to first-line treatment were found to be prog-
nostic variables by univariate analysis (Table III). On multivariate
analyses heavy chain type, ISS, BMPC, extramedullary plasmacytoma,
and serum creatinine were identified as significant prognostic factors.
In addition, novel drug exposure as a first-line treatment, transplanta-
tion, 13q deletion by conventional cytogenetics, and the presence of
any adverse FISH abnormality including t(4;14), t(14;16), and 17p dele-
tions were also identified as important prognostic factors (Table V).
 Discussion
MM is characterized by its unique clinical characteristics of bone
lesions and the presence of M-protein. The ethnic difference in the
incidence of MM has been shown in US SEER data and IARC data,
with Asians having a relatively lower incidence of MM [1]. Although
Figure 1. Overall survival of Asian myeloma patients. A: Overall survival of
3405 Asian myeloma patients. Median OS was 47 months. B: OS according
to the year of diagnosis. [1986–2001 (n5486) vs. 2002–2011 (n52,919), 35
vs. 49 months, P<0.001]. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
TABLE II. Cytogenetics of the Patients
N (%) OS (months) P value
Conventional
cytogenetics
Total 1681 47
Normal 1135 (67.5%) 53 <0.001
Abnormal 546 (32.5%) 34
Cytogenetic
ploidy
Total 1660 47
Diploidy 1164 (70.1%) 53 <0.001
Hyperdiploidy 245 (14.8%) 37
Nonhyperdiploidy 251 (14.8%) 28
Cytogenetic 13q
deletion
Total 1647 48
Yes 201 (12.7%) 24 <0.001
No 1446 (87.8%) 52
FISH t(11;14) Total 683 54
Yes 119 (17.4%) 47 0.936
No 564 (82.6%) 54
FISH t(4;14) Total 637 53
Yes 67 (10.5%) 34 0.02
No 570 (89.5%) 60
FISH t(14;16) Total 498 66
Yes 22 (4.4%) NR 0.365
No 476 (95.6%) 66
FISH 17p deletion Total 854 51
Yes 114 (13.3%) 38 0.061
No 740 (87.7%) 54
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this lower genetic susceptibility has been partly attributed to genetic
polymorphisms [14,15], the exact reason has not been elucidated.
Recently, there is growing evidence that MM incidence rates are
increasing in some Asian countries such as South Korea and Taiwan
[2,3]. The South Korean experience is particularly interesting. The
incidence of MM in South Korea has doubled over a 10-year period,
and based on recent national cancer registry data increase was 10
times compared with MM incidence of 20 years ago. The difference
TABLE III. Treatment and Prognostic Significance
N OS (months) P value N OS (months) P value
ASCT (N5 3,371) Yes 666 (19.8%) 79 <0.001
No 2705 (80.2%) 41
First-line treatment
(N52,970)
New drugs 1067 (35.9%) 49 0.098 IMiDs-based 502 (16.9%) 49 0.286
Bortezomib-based 447 (15.1%) 51
Bortzomib andIMiDs 118 (4.0%) 53
conventional 1903 (64.1%) 48 conventional 1903 (64.1%) 48
Response to first-line
treatment (N5 2,660)
 VGPR 821 (30.9%) 69 <0.001 CR 450 (16.9%) 68 <0.001
nCR 124 (4.7%) 64
VGPR 247 (9.3%) 77
PR 1053 (39.6%) 50 PR 1053 (39.6%) 50
< PR 786 (29.5%) 34 MR 102 (3.8%) 42
SD 481 (18.1%) 34
PD 203 (7.6%) 22
ASCT, autologous stem cell transplantation; IMiDs, immune modulating drugs; CR, complete response; VGPR, very good partial response; PR, partial
response; MR, minor response; SD, stable disease; PD, progressive disease.
TABLE IV. Univariate Analysis for Overall Survival
Total Median OS (months) P value
Age N 3,405
<65 1,992 (58.5%) 55 <0.001
65 1,413 (41.5%) 37
Gender Female 1,513 (44.4%) 50 0.262
Male 1,892 (55.6%) 45
Type N 3,129
IgG 55.2% 52 0.002
IgA 22.0% 43
IgD 3.1% 33
LCD 17.9% 43
Nonsecretory 1.9% 67
other 0.5%
Hemoglobin N 3271
10.0 g/dL 1,287 (39.3%) 64 <0.001
<10.0 g/dL 1,984 (60.7%) 40
Platelets N 3157
<70 3 109/L 277 (8.8%) 34 0.001
70 3 109/L 2,880 (91.2%) 48
Bone lesion N 2661
Yes 1,601 (60.2%) 48 0.554
No 1,969 (39.8%) 52
Extramedullary
plasmacytoma
N 3,093
presence 476 (15.4%) 40 0.01
absence 2,617 (84.6%) 49
Serum creatinine N 3173
<2.0 mg/dL 2,430 (76.6%) 52 <0.001
2.0 mg/dL 741 (23.4%) 31
Serum albumin N 3,030
<3.5 g/dL 1,575 (52%) 40 <0.001
3.5 g/dL 1,455 (48%) 58
Serum beta
2-microglobulin
N 2,857
<3.5 mg/L 987 (34.5%) 68 <0.001
3.5–5.5 mg/L 668 (23.4%) 52
>5.5 mg/L 1,202 (42.1%) 33
ISS N 2,984
I 594 (19.9%) 80 <0.001
II 1,076 (36.1%) 53
III 1,314 (44%) 33
Serum calcium 3,063
10.5 mg/dL 512 (16.7%) 33 <0.001
<10.5 mg/dL 2,551 (83.3%) 50
Plasma cells of BM N 3,042
<30% 1,249 (41.1%) 59 <0.001
30–70% 1,232 (40.5%) 45
>70% 561 (18.4%) 34
LCD, light chain disease; ISS, international staging system; BM, bone marrow.
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is even more striking when reference is made to the national mortality
data and incidence survey by their society of hematology [2]. The inci-
dence of total cancers in South Korea increased two times during last
10 years, while, the incidence of acute leukemias was almost static dur-
ing the same period. As a result, MM is currently ranked as the third
most common hematologic malignancy, surpassing acute lymphoblas-
tic leukemia (ALL) in 2007 and approaching the incidence of acute
myeloid leukemia (AML) [16]. Exactly the same observation, doubling
of MM incidence in last 10 years, has been reported in Taiwan, which
has a similar socioeconomic development status as South Korea, but
different ethnic groups [3]. Other countries in Asia have also reported
an increasing incidence of MM, although the degree of increase has
varied. The exact reasons for this increase have yet to be explored. Of
course increased detection may have played an important role, espe-
cially in early period. The other two speculated factors are industriali-
zation and aging. Industrialization is associated with increased
exposure to chemical carcinogens, ionizing radiation, air pollution,
Westernized diets, and obesity, which are known predisposing factors
for developing MM [17]. Aging is suspected to be another important
contributing factor. MM is considered a disease of the elderly and its
incidence increases sharply with age, as shown in the SEER as well as
the South Korean data [16]. Japan is a good example for this observa-
tion. Although Japan has a moderate age-adjusted incidence rate of
MM, its crude incidence is the highest among Asian countries because
the country has a larger elderly population. In the same vein, South
Koreans have been witnessing an 18-year increase in the median life
expectancy over a 37-year observation period, an unprecedented
change that is suspected to be strongly associated with the increased
rates of MM. One more thing we should consider is the incidence of
monoclonal gammopathy of undetermined significance (MGUS)
among Asian countries. Surprisingly, the incidence of MGUS is almost
equivalent or only slightly lower than what has been reported in West-
ern countries, although the number of studies is very limited [18–20].
Considering that MM is almost always preceded by MGUS,[21] the
reported incidence of MGUS in Asian countries would lead us to
expect that the incidence of MM will further increase in the near
future. When we consider the enormous population of Asia, with 4
billion people in 47 countries, and its growing economy, the impact of
MM on health care systems is expected to increase dramatically.
We sought to identify the characteristics of MM in Asian regions
and compare them with the published data on Western counterparts
[22]. As patients included in our study come from major tertiary cen-
ters in Asia, our data may not representative of the true characteris-
tics of MM in Asia due to selection bias. Nonetheless, this is the very
first pooled analysis of MM in Asian countries and our survival data
may reflect the possible outcomes of MM patients who are able to
receive proper MM care in tertiary centers where resources are not
limited. The median age of this cohort was 62, which is slightly lower
than that in Western reports [22]. Japan showed the highest median
age, which seems to reflect their larger elderly population. The
median age of MM seems to be closely related to the median life
expectancy of the population. In Korea, for example, the median age
of MM was only 54 years in the 1960s, which had increased to 67
years in 2010. During the same period, the median life span of the
Korean population increased from 64 years to 81years, which seems
to be related with the median age of MM. Since South Korea is rap-
idly moving from an aging society to an aged society, this trend is
expected to continue. Most countries showed a greater number of
males affected by MM. Although Thailand’s cohort showed an inter-
esting female predominance, this could be related to the small size of
the cohort. In fact, female predominance has not been reported in
other studies from Thailand. Bone lesions were detected in 60.2% of
the patients. Japan reported the highest rates of bone lesions while
Thailand reported the lowest. These trends could be related to the
availability of imaging facilities for MRI or PET scans, as well as
reimbursement issues. Significant anemia and thrombocytopenia were
observed in 60.7% and 8.8%, respectively, of the patients, and extra-
medullary plasmacytoma was observed in 15.5% of the patients, with
South Korea and Thailand reporting slightly higher incidences. The
incidence of hypercalcemia, hypoalbuminemia, significant azotemia,
and M-protein were not significantly different from the Western liter-
ature [22]. The rates of patients with ISS stages I/II/III were 19.9%/
36.1%/44%, respectively, which represented a higher incidence of
advanced disease compared to the original ISS reports which showed
incidences of ISS stages I/II/III of 28%/33%/39%, respectively. This
might be due to the relatively later diagnosis of MM in Asia com-
pared to Western countries or a later presentation of patients to the
tertiary centers involved in this study. Cytogenetic profiles of our
patients also showed trends similar to the Western literature [23].
Singapore reported the highest incidences of abnormal cytogenetics
and 13q deletions, and this might reflect their higher quality of labo-
ratories. FISH data was available in only a minority of the patients
TABLE V. Multivariate Analysis for Overall Survival
HR 95% CI p value
Baseline characteristicswith
treatment (N5 1,580)
Heavy chain type others vs. IgG 1.228 1.049–1.437 0.01
ISS II vs. I 1.299 1.029–1.64 0.028
ISS III vs. I 1.847 1.43–2.385 <0.001
Plasma cells in BM >70% vs. <30% 1.332 1.06–1.675 0.014
Plasmacytoma presence vs. absence 1.528 1.228–1.902 <0.001
Scr 2.0 vs. <2.0 mg/dl 1.25 1.009–1.548 0.042
First-line Treatment New drug vs. chemotherapy 0.675 0.544–0.826 <0.001
Transplantation yes vs. no 0.456 0.372–0.56 <0.001
Baseline characteristics with
conventional cytogenetics
(N5 1,239)
age65 vs. <65 1.531 1.295–1.809 <0.001
heavy chain type others vs. IgG 1.255 1.063–1.481 0.007
ISS II vs. I 1.449 1.133–1.854 0.003
ISS III vs. I 1.751 1.326–2.312 <0.001
Plasmacytoma presence vs. absence 1.372 1.081–1.741 0.009
Scr2.0 vs. <2.0 mg/dl 1.459 1.143–1.862 0.002
13q deletion yes vs. no 1.873 1.421–2.469 <0.001
Baseline characteristics with
FISH (N5441)
age65 vs. <65 1.546 1.109–2.154 0.01
ISS II vs. I 1.86 1.049–3.3 0.034
ISS III vs. I 3.096 1.704–5.626 <0.001
platelets <70 3 109 vs. 70 3 109/L 1.665 1.06–20616 0.027
Plasmacytoma presence vs. absence 2.025 1.333–3.076 0.001
t(4;14), t(14;16) or 17p deletion yes vs. no 1.488 1.027–2.155 0.035
ISS, international staging system; BM, bone marrow; Scr, serum creatinine.
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because of differences in the facilities of the participating centers.
FISH abnormalities such as t(11;14), t(4;14), t(14;16) and 17p dele-
tions were also found at similar rates when compared with Western
literature. However, the rate of 17p deletions in the Chinese cohort
was 29.2%, which is unusually high. This may reflect later diagnosis
or presentation of patients since P53 deletion is a late genetic event
in myeloma development. This observation needs further confirma-
tion to determine if there could be an ethnic variation. However, data
from Hong Kong and Singapore, 2 regions with a predominant Chi-
nese ethnic population do not show a higher incidence of 17p dele-
tion. Conventional therapy was performed in 64.1% of the patients
while novel drugs were given in 36%. Conventional therapy consisted
of various combinations with alkylating agents such as melphalan or
cyclophosphamide, vincristine, doxorubicin and steroids. The Chinese
cohort had more populations exposed to novel drugs because of
patients receiving care in tertiary hospitals with many clinical trials.
Although the median age of our cohort was 62, only 19.8 % of the
patients underwent stem cell transplantation (SCT), mainly ASCT.
These rates seemed to be related to the availability and experience of
transplantation facilities. South Korea had the highest rate of SCT
among the countries studied. The overall survival of SCT was 79
months, which is better than that of conventional therapy (41
months). Although the impact of novel agents in the first-line treat-
ment was not significant in univariate analysis (49 vs. 48 months,
P5 0.098), it was significant in multivariate analysis (P< 0.001). We
also observed survival improvement in patients who were diagnosed
in recent 10 years as the report from Mayo clinic [24].
The clinical parameters affecting overall survival were not dif-
ferent from the Western data. Our study corroborates Western
data with regard to the prognostic significance of baseline charac-
teristics like heavy chain type, ISS, BMPC, presence of extrame-
dullary plasmacytoma, and serum creatinine. Novel drug exposure
as a first-line treatment, transplantation, 13q deletion by conven-
tional cytogenetics, and the presence of t(4;14), t(14;16), or 17p
deletion were also identified as important prognostic markers
among Asians. In fact, some of the Asian cytogenetics data were
already incorporated in a recent global trial and did not differ
from Western data [25].
In summary, there are no unique clinical characteristics of MM
that are peculiar to Asian patients. Although some country-specific
characteristics were observed, these need to be further verified in
future studies. Notwithstanding the selection bias and the limitation
of the study population in representing true Asian MM characteris-
tics, this project highlights that by availing proper MM care to Asian
MM patients, a reasonable clinical outcome can be achieved and this
will provide a platform for the design of future studies and clinical
trials involving Asian MM patients.
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